Palm Beach, FL 12/2/11 (StreetBeat) --Positron Corporation (OTCBB: POSC.OB), a leading molecular imaging company specializing in the field of nuclear cardiology, is pleased to announce that Amerinet has awarded a Group Purchasing Agreement for their PosiRx system to begin January 1, 2012 for a three-year period. Amerinet is a Group Purchasing Organization (GPO), which enters into arrangements for the purchase of products and services on behalf of its member facilities. Amerinet provides a broad portfolio of agreements, products and services capable of serving healthcare organizations, both hospitals and non-hospitals alike. Amerinet's objective is to secure new opportunities with emerging technology vendors in order to reduce costs and improve efficiencies to its member network.
Positron's objective is to offer the PosiRx System throughout Amerinet's network of over 50,000 members. Positron's PosiRx technology will meet the needs of those Amerinet members desiring efficient radiopharmaceutical solutions for their cardiac SPECT pharmacy needs.
"We believe the PosiRx system will impact and redefine the industry by offering a more efficient and economical alternative to the current nuclear pharmacy model. We are excited to work with Amerinet and their extensive member network, as our innovative solutions are well-aligned with their vision," stated Michael Stewart , Positron's Director of Radiopharmaceutical Business Development.
PosiRx is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. It was created to simplify and control the procedures associated with compounding radiopharmaceuticals. PosiRx is the first system of its kind to offer a complete and comprehensive automated solution in nuclear medicine.
StreetBeat Disclaimer
No comments:
Post a Comment